Akademik Veri Yönetim Sistemi
16th International Gastric Cancer Conference, Amsterdam, Hollanda, 7 - 10 Mayıs 2025, ss.893, (Özet Bildiri)
Introduction: Based on current data, the impact of adding radiotherapy(RT) to adjuvant treatment following the fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in locally advanced gastric cancer remains unclear. In our study, we assessed the effects of adjuvant RT on local control and survival outcomes in patients who completed both neoadjuvant and adjuvant FLOT treatments. Methodology: Between January 2018 and June 2024, 32 patients (Group-1) who underwent surgery and adjuvant chemotherapy after neoadjuvant chemotherapy and 52 patients (Group-2) who underwent chemoradiotherapy after surgery and adjuvant chemotherapy were included. Adjuvant RT was recommended for all patients, but those in Group-1 either declined it for personal reasons or completed adjuvant chemotherapy at facilities where RT was not included in the treatment protocol. Results: Median follow-up time was 26(9-94) months. Two- and three-year overall survival(OS) and disease-free survival(DFS) rates were 65.5% and 54.4%, 57.3% and 51.1% in Group-1, 86.5% and 74.7%, 76.7% and 65.7% in Group-2 patients (p=0.170,p=0.191). However, among patients with positive nodal involvement after surgery, the 2- and 3-year OS and DFS rates were 57.4% and 49.4%, 45% and 42% in Group-1, 79.7% and 68.3%, 68% and 61% in Group-2 (p=0.027,p=0.045) patients. Conclusion:Although OS did not significantly differ between groups, adjuvant RT improved survival outcomes in node-positive patients. Currently, there is no randomized study in the literature that explores the addition of RT to the FLOT regimen after surgery. The observed survival benefit in node-positive patients underscores the potential role of adjuvant RT and warrants further investigation in a randomized trial.